The primary efficacy endpoint for the 2 pivotal studies was the proportion of subjects with plasma HIV-1 RNA 50 c/mL at Week 48 using the Snapshot algorithm for the ITT-E Population.Proportion of subjects with plasma HIV-1 RNA 50 c/mL at Week 24 using the Snapshot algorithm for the ITT-E population;By Baseline third agent treatment class;Although not specified in the protocol, the proportion of subjects who were classified as Snapshot virological failure at Week 48 was also evaluated.The relevant exploratory efficacy endpoints for the first 48 weeks of the study included the following:Proportion of subjects by patient subgroup(s)(e.g., by age, gender, Baseline CD4+)with plasma HIV-1 RNA 90% power to show non-inferiority for the proportion of subjects with plasma HIV-1 RNA